173 related articles for article (PubMed ID: 32897765)
1. Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus
Shimabukuro Ho R; Mioti Sebastião M; Venezian de Carvalho JP; Neves T; Nussbaum M
J Med Econ; 2020 Nov; 23(11):1340-1344. PubMed ID: 32897765
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
Rugo HS; Loi S; Adams S; Schmid P; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Winer EP; Kockx MM; Peeters D; Chui SY; Lin JC; Nguyen-Duc A; Viale G; Molinero L; Emens LA
J Natl Cancer Inst; 2021 Nov; 113(12):1733-1743. PubMed ID: 34097070
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.
Chisaki Y; Kuwada Y; Matsumura C; Yano Y
Clin Drug Investig; 2021 Apr; 41(4):381-389. PubMed ID: 33674955
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer.
Phua LC; Lee SC; Ng K; Abdul Aziz MI
BMC Health Serv Res; 2020 Jun; 20(1):581. PubMed ID: 32580722
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
Kang C; Syed YY
Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
[TBL] [Abstract][Full Text] [Related]
7. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
[TBL] [Abstract][Full Text] [Related]
8. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).
Iwata H; Inoue K; Kaneko K; Ito Y; Tsugawa K; Hasegawa A; Nakagawa S; Kuratomi H; Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(12):1083-1091. PubMed ID: 31612909
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
[TBL] [Abstract][Full Text] [Related]
10. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
Liu X; Lang Y; Liao Y; Zhu Y
Front Public Health; 2021; 9():756899. PubMed ID: 34778188
[No Abstract] [Full Text] [Related]
13. First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
Weng X; Huang X; Li H; Lin S; Rao X; Guo X; Huang P
Am J Clin Oncol; 2020 May; 43(5):340-348. PubMed ID: 32028340
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
15. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
Sigurjonsdottir G; De Marchi T; Ehinger A; Hartman J; Bosch A; Staaf J; Killander F; Niméus E
Breast Cancer Res; 2023 Oct; 25(1):123. PubMed ID: 37817263
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.
Wu B; Ma F
Ther Adv Med Oncol; 2020; 12():1758835920916000. PubMed ID: 32426048
[TBL] [Abstract][Full Text] [Related]
17. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.
Narayan P; Wahby S; Gao JJ; Amiri-Kordestani L; Ibrahim A; Bloomquist E; Tang S; Xu Y; Liu J; Fu W; Song P; King-Kallimanis BL; Hou S; Gong Y; Kalavar S; Ghosh S; Philip R; Goldberg KB; Theoret MR; Blumenthal GM; Kluetz PG; Sridhara R; Pazdur R; Beaver JA
Clin Cancer Res; 2020 May; 26(10):2284-2289. PubMed ID: 32001481
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level.
Giuliani J; Mantoan B; Bonetti A
J Oncol Pharm Pract; 2021 Jul; 27(5):1245-1247. PubMed ID: 34018861
[TBL] [Abstract][Full Text] [Related]
19. Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer.
Lee SE; Park HY; Lim SD; Han HS; Yoo YB; Kim WS
J Breast Cancer; 2020 Jun; 23(3):303-313. PubMed ID: 32595992
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer.
Li J; Zhang T; Lu P; Zhao J; Chen L; Jiang J
Immunotherapy; 2020 Jul; 12(10):705-713. PubMed ID: 32522057
[No Abstract] [Full Text] [Related]
[Next] [New Search]
